BioLargo Inc (BLGO)
OTHER OTC:BLGO
BLGO Stock Chart & Stats
$0.19
<$0.01(0.17%)
At close: 4:00 PM EST
$0.19
<$0.01(0.17%)
Day’s Range― - ―
52-Week Range$0.14 - $0.26
Previous CloseN/A
Volume222.28K
Average Volume (3M)570.01K
Market Cap
$45.98M
Enterprise Value$50.15M
Total Cash (Recent Filing)$3.88M
Total Debt (Recent Filing)$3.51M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
May 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding319,750,850
10 Day Avg. Volume632,227
30 Day Avg. Volume570,010
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)14.00
Price to Sales (P/S)7.29
P/FCF Ratio-6.78
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.46
Enterprise Value/Gross Profit14.72
Enterprise Value/Ebitda-3.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$4.90M
Bulls Say, Bears Say
Bulls Say
AEC PFAS Regulatory ValidationEPA and NJDEP-monitored field validation gives the AEC PFAS system regulatory credibility that supports municipal procurement cycles and long-term adoption. Regulatory engagement reduces technical uncertainty, can accelerate approvals and contracting timelines, and underpins repeatable sales to public utilities over months.
Clyra Medical Commercial LaunchFDA clearance plus an exclusive distributor and a paid stocking order mark a transition from development to commercialization. This establishes medical-channel go-to-market capabilities and initial revenue traction, supporting recurring consumable or device replenishment sales and scaling opportunities over the next several quarters.
Sustained Gross MarginsStable mid-40% gross margins indicate inherent product economics that can absorb SG&A or commercialization spend as revenue grows. Margin durability supports incremental profitability as volumes rise, enables reinvestment in sales/engineering, and reduces the break-even burden compared to lower-margin businesses.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external financing or dilution to fund operations and commercialization. Accelerating cash burn in 2025 elevates financing risk and constrains the company's ability to invest ahead of revenue inflection points without eroding shareholder equity or taking costly capital.
Weakened Equity CushionA very low equity base limits the firm's ability to withstand further losses or operational setbacks. With minimal cushion, unexpected adverse events or slower-than-expected commercial adoption could rapidly force dilutive financing, impair strategic flexibility, and increase counterparty or supplier concerns over longer-term viability.
Partner/Licensing Execution RiskThe termination of a major licensee and ensuing litigation removed material revenue and highlights dependence on third-party commercialization. This partner execution risk undermines predictable revenue scaling via licensing, increases legal and collection uncertainty, and complicates future partner negotiations and deal structuring over the coming quarters.
BioLargo News
BLGO FAQ
What was BioLargo Inc’s price range in the past 12 months?
BioLargo Inc lowest stock price was $0.14 and its highest was $0.26 in the past 12 months.
What is BioLargo Inc’s market cap?
BioLargo Inc’s market cap is $45.98M.
When is BioLargo Inc’s upcoming earnings report date?
BioLargo Inc’s upcoming earnings report date is May 20, 2026 which is in 35 days.
How were BioLargo Inc’s earnings last quarter?
BioLargo Inc released its earnings results on Mar 05, 2026. The company reported -$0.012 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.002.
Is BioLargo Inc overvalued?
According to Wall Street analysts BioLargo Inc’s price is currently Overvalued.
Does BioLargo Inc pay dividends?
BioLargo Inc does not currently pay dividends.
What is BioLargo Inc’s EPS estimate?
BioLargo Inc’s EPS estimate is -0.01.
How many shares outstanding does BioLargo Inc have?
BioLargo Inc has 319,750,850 shares outstanding.
What happened to BioLargo Inc’s price movement after its last earnings report?
BioLargo Inc reported an EPS of -$0.012 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -5.587%.
Which hedge fund is a major shareholder of BioLargo Inc?
Currently, no hedge funds are holding shares in BLGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLargo Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.75%
12-Months-Change
Fundamentals
Return on Equity
-174.59%
Trailing 12-Months
Asset Growth
-20.95%
Trailing 12-Months
Company Description
BioLargo Inc
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
BLGO Company Deck
BLGO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable commercialization and validation milestones (Clyra launch and clinical data, AEC municipal install with EPA monitoring, Cellinity MOUs and technology validation, service revenue doubling, and preserved cash) against material near-term financial challenges (2025 revenue decline to $7.8M, $15.2M net loss, a booked credit loss, Pooph license termination and litigation, and diminished shareholders' equity). Management emphasizes transition from development to commercialization and several near-term catalysts for 2026, but the significant 2025 financial deterioration and ongoing legal/partner risks temper the outlook.View all BLGO earnings summariesTechnical Analysis
Ownership Overview
12.91% Insiders
0.04% Other Institutional Investors
87.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---